Summary
• Clearmind Medicine Inc. (CMND) shares rose 6.1% in pre-market trading after reporting positive results from its Phase I/IIa clinical trial for CMND-100, a treatment for alcohol use disorder.
• The company has also filed for a patent in Israel for a combination therapy targeting depression, indicating an expansion into mental health treatments.
• Despite the positive trial news, CMND’s stock has faced a significant decline of 51.1% year-to-date and 90% from its 52-week high, although trading volume increased notably in pre-market activity.
Clearmind Medicine Inc. (NASDAQ: CMND) is seeing a pre-market price movement of 6.1%, trading at $0.2295, compared to the last close of $0.2164. The rise comes after the company announced progress in its clinical trials for a treatment targeting alcohol use disorder.
Clinical Trial Results Propel Stock Higher
On November 18, 2025, Clearmind reported positive top-line results from the first cohort of its Phase I/IIa clinical trial for CMND-100, its novel non-hallucinogenic drug candidate aimed at treating alcohol use disorder (AUD). This development is a significant milestone for the company as it progresses its innovative therapeutic pipeline, which focuses on major under-treated health issues. The announcement has resonated well in the market, with over 814,540 shares trading in pre-market activity.
Recent Company Announcements
In addition to the aforementioned results, Clearmind has been active in securing intellectual property protections and regulatory approvals. The company filed an Israeli patent application for a combination therapy targeting depression just a day prior to the trial results announcement. This filing highlights Clearmind’s focus not only on AUD but also on expanding its therapeutic offerings in mental health treatments, addressing a critical area with significant market potential.
Market and Technical Picture
Clearmind’s shares have faced considerable downward trend over the past year, showing a 51.1% decline year-to-date and a staggering 90% drop from the 52-week high. The stock is currently trading well below its 20-day, 50-day, and 200-day SMAs, which suggest a persistent bearish sentiment among investors. With the reported increase in volume surpassing both the 10-day average of 64,097,555 and the 3-month average of 7,801,007, traders may be reassessing their positions.
Outlook
With shares reacting positively to the latest trial results, investors appear to be gaining renewed confidence in Clearmind’s capabilities to offer innovative treatments. Their recent announcements indicate a proactive approach in the clinical and regulatory landscape, positioning the company for potential future growth.